Meta-analysis reveals SGLT2 inhibitors raise hemoglobin and hematocrit levels

A large meta-analysis led by Dr. Michele Eisenga has found that SGLT2 inhibitors, drugs commonly prescribed for type 2 diabetes, heart failure, and chronic kidney disease, consistently increase hemoglobin and hematocrit levels. This research provides new insights into the effects of these medications on blood and iron parameters.

Originally published by gnews